



L Number	Hits	Search Text	DB	Time stamp
5	1060	544/101, 544/105	USPAT; US-PGPUB	2003/09/23 10:53
6	17727	borontrifluoride or (boron adj trifluoride)	USPAT; US-PGPUB	2003/09/23 10:49
8	69	(544/101, 544/105) and (borontrifluoride or (boron adj trifluoride))	USPAT; US-PGPUB	2003/09/23 10:52
10	330	544/101	USPAT; US-PGPUB	2003/09/23 11:34



chain nodes :  
 11 12 13 14 15 16 17 18 19 20 21 22 23  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 10  
 chain bonds :  
 4-20 7-12 8-11 8-23 9-21 9-22 12-13 13-14 13-17 14-15 14-16 17-18 17-19  
 ring bonds :  
 1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10  
 exact/norm bonds :  
 1-10 6-7 7-8 7-12 8-9 8-11 9-10 14-15 14-16 17-18 17-19  
 exact bonds :  
 4-20 8-23 9-21 9-22 12-13 13-14 13-17  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6

Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS  
 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS  
 21:CLASS 22:CLASS 23:CLASS

fragments assigned reactant/reagent role:  
 containing 1

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \*

FILE 'HOME' ENTERED AT 09:50:37 ON 23 SEP 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:50:45 ON 23 SEP 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 SEP 2003 HIGHEST RN 591204-55-6  
 DICTIONARY FILE UPDATES: 22 SEP 2003 HIGHEST RN 591204-55-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 10070556.str

L1 STRUCTURE UPLOADED

=> file casreact

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.40	0.61

FILE 'CASREACT' ENTERED AT 09:51:15 ON 23 SEP 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1907 - 21 Sep 2003 VOL 139 ISS 12

Some records from 1974 to 1991 are derived from the ZIC/VINITI data file and provided by InfoChem and some records are produced using some INPI

data from the period prior to 1986.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Crossover limits have been increased. See HELP RNCROSSOVER for details.

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

```
=> s 11
SAMPLE SEARCH INITIATED 09:51:22 FILE 'CASREACT'
SCREENING COMPLETE -      0 REACTIONS TO VERIFY FROM      0 DOCUMENTS
}
100.0% DONE      0 VERIFIED      0 HIT RXNS      0 DOCS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                      BATCH **COMPLETE**
PROJECTED VERIFICATIONS:      0 TO      0
PROJECTED ANSWERS:      0 TO      0

L2      0 SEA SSS SAM L1 (      0 REACTIONS)


=> s 11 sss full
FULL SEARCH INITIATED 09:51:33 FILE 'CASREACT'
SCREENING COMPLETE -      72 REACTIONS TO VERIFY FROM      13 DOCUMENTS
}
100.0% DONE      72 VERIFIED      22 HIT RXNS      10 DOCS
SEARCH TIME: 00.00.01

L3      10 SEA SSS FUL L1 (      22 REACTIONS)

=> d fhit ibib abs tot
```

L3 ANSWER 1 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(8) OF 45 ...W ==&gt; Y...

RX(8) RCT W 106939-43-9  
RCT Z 462-34-0 THF.BF3

PRO Y 113348-94-0

SOL 108-24-7 Ac2O

NTE cyclization at 140.degrees. for 1 h

ACCESSION NUMBER: 1371232675 CASREACT

TITLE: Process for preparation of optically active 2-hydroxypropoxylamine derivatives as intermediates for levofloxacin via enzymic or microbial

stereoselective hydrolysis of racemic lactic acid ester

INVENTOR(S): Sato, Kouji; Yagi, Tsutomu; Kubota, Kazuo; Imura, Akihiro

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070726	A1	20020912	WO 2002-JP2054	20020306
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZM, ZW, ZY				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CR, GA, GN, GW, ML, MR, NE, SN, TD, TG				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CR, GA, GN, GW, ML, MR, NE, SN, TD, TG


L3 ANSWER 1 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CR, GA, GN, GO, GW, HL, MR, NE, SN, TD, TG  
PRIORITY APPLN. INFO.: JP 2001-63945 20010307  
OTHER SOURCE(S): MARPAT 137:232675  
GI

AB Treatment of a racemic lactate deriv. of formula  $\text{MeCH}(\text{OR2})\text{CO}_2\text{R1}$  ( $\text{R1} = \text{C1-6 alkyl}; \text{R2} = \text{hydroxy-protecting group}$ ) with an enzyme having an ability to hydrolyze an ester asym. causes specific hydrolysis of the ester moiety of one of the optical isomers constituting the racemic lactate deriv. to give optically active lactic acid esters (I;  $\text{R1}, \text{R2} = \text{same as above}$ ). The alkyl lactate I is reduced by metal borohydride in the presence of a primary alc. in nonalcoholic solvent to optically active 2-hydroxypropanol (II;  $\text{R2} = \text{same as above}$ ) which is condensed with trihalonitrobenzene (III;  $\text{X1-X3} = \text{halo}$ ) in the presence of a base to give 3,4-dihalo-2-(2-hydroxypropoxy)nitrobenzene deriv. (IV;  $\text{R} = \text{NO}_2$ ;  $\text{R2}, \text{X1}, \text{X2} = \text{same as above}$ ). Simultaneous conversion of the nitro group into the amino group and cleavage of the protecting group gives 3,4-dihalo-2-(2-hydroxypropoxy)aniline IV ( $\text{R} = \text{NH}_2$ ,  $\text{R2} = \text{H}$ ;  $\text{X1}, \text{X2} = \text{same as above}$ ) which is converted into levofloxacin (antibacterial) in several steps. Thus, 300 mg 2-benzylxypiprocaine acid Et ester was suspended in 0.1 M phosphate buffer (pH 6.5) and treated with 6 mg lipase (Biochem. Industry Co.) at 30.degrees. for 24 h to give 102 mg (R)-2-benzylxypiprocaine acid Et ester (98.8% ee) which (100 mg) was reduced by NaBH4 in 0.15 mL MeOH and 0.8 mL toluene at 40.degrees. for 3 h to give 79 mg (R)-2-benzylxypiprocaine (V) (99% ee). A soln. of 4.0 g V and 4.13 g 2,3,4-trifluoroniobenzene in 40 mL toluene was added to a suspension of 5.40 g KOH and 3.33 g K2CO3 in 180 mL toluene under ice-cooling and stirred at the same temp. for 1 h to give 7.55 g (R)-3,4-difluoro-2-(2-benzylxypiprocaine)nitrobenzene which (1.0 g) was hydrogenated over 1.0 g 5% Pd/C in 10 ethanol under hydrogen atm. for 6 h to give 600 mg (R)-3,4-difluoro-2-(2-hydroxypropoxy)aniline (99.8% ee).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(3) OF 10 ...G ==&gt; J...



RX(3) RCT G 106939-43-9

RCT K 109-63-7 BF3-Et2O

PRO J 113348-94-0

SOL 108-24-7 Ac2O

ACCESSION NUMBER: 134:222719 CASREACT

TITLE: Process for the preparation of benzoxazine derivatives and intermediates therefor

INVENTOR(S): Sato, Kouji; Takayangi, Yoshihiro; Okano, Katsuhiro; Nakamura, Keiji; Imura, Akihiro; Itoh, Mikihiro; Yagi, Tsutomu; Kobayashi, Yukinari; Nagai, Tomoyuki

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001018005	A1	20010315	WO 2000-JP6094	20000907
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LX, LV, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZM, ZW, ZY				
R: BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CR, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1211257	A1	20020605	EP 2000-957001	20000907
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CR, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2002121179	A2	20020423	JP 2000-273449	20000908
JP 2001169841	A2	20010619	JP 2000-297799	20000929
NO 2002001124	A	20020508	NO 2002-1124	20020306

L3 ANSWER 2 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)

PRIORITY APPLN. INFO.: JP 1999-253958 19990908  
JP 1999-278019 19990930  
JP 2000-239256 20000808  
JP 2000-239262 20000808  
WO 2000-JP6094 20000907OTHER SOURCE(S): MARPAT 134:222719  
GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention provides an industrially advantageous process for the prepn. of antimicrobial drugs, specifically (3S)-9-halo-3-methyl-1-piperazinyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (I;  $X = \text{halo}$ ) (e.g. levofloxacin), and industrially advantageous processes for the prepn. of intermediates of antimicrobial drugs. The process involves, e.g., cyclization of dialkyl [(3,4-dihydro-2H-1,4-benzoxazin-4-yl)methylene]malonate deriv. (II;  $\text{X1}, \text{X2} = \text{halo}$ ;  $\text{R} = \text{C1-6 alkyl}$ ) by treatment with Et20-BF3 and (3S)-9,10-dihalo-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid-BF3 complex (III;  $\text{X1}, \text{X2} = \text{same as above}$  with 4-methylpiperazine). Thus, (2S)-2-(2,3,4-trifluorosulfonyl)-1-propanol, ethoxymethylemalonic acid di-Et ester, and tetrabutylammonium chloride were dissolved in acetone, treated with K2CO3, and stirred at room temp. for 1.5 h to give 84% di-Et [2,3,4-trifluorol(1S)-2-hydroxy-1-methylethyl]amino]methylemalonate (IV). A soln. of IV in DMF was added dropwise to potassium tert-butoxide in DMF under ice-cooling and stirred at 60.degrees. for 18 h to give 79% II ( $\text{X1} = \text{X2} = \text{F}$ ;  $\text{R} = \text{Et}$ ) which was mixed with Ac2O, treated with Et20-BF3 at 140.degrees., and stirred at the same temp. for 1 h to give III ( $\text{X1} = \text{X2} = \text{F}$ ). The latter compd. was dissolved in DMSO, treated with Et3N and N-methylpiperazine, stirred at room temp. for 17 h, and concd. in vacuo to dryness, and the residue was washed with Et20, dissolved in 95% ethanol contg. Et3N, refluxed for 8 h, cooled, and evapd. in vacuo to dryness. The residue was dissolved in 5% HCl and extd. with CHCl3, and the aq. layer was adjusted at pH 11 with 1 M NaOH and then at pH 7.4 with 1 M HCl, and extd. with CHCl3 to give levofloxacin.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(8) OF 55 ...W ==&gt; AA...



RX(8) RCT W 106939-43-9

PRO AA 106939-34-8

NTE reaction run in PPE/stereoselective synthesis

ACCESSION NUMBER: 132:22935 CASREACT

TITLE: A practical stereoselective synthesis of (S)-(-)-ofloxacin


AUTHOR(S): Yang, Yu-Shei Ji, Ru-Yun Chen, Kai-Xian  
CORPORATE SOURCE: Shanghai Institute of Material Medica, Chinese Academy  
of Sciences, Shanghai, 200031, Peop. Rep. ChinaSOURCE: Chinese Journal of Chemistry (1999), 17(5), 539-544  
CODEN: CJOCFV; ISSN: 1001-604X

PUBLISHER: Science Press

DOCUMENT TYPE: Journal

LANGUAGE: English


GI



**AB** A very efficient and practical procedure for prpn. of (S)-(-)-ofloxacin (I) has been developed [10 steps, overall yield 45%]. The key step of this approach is the regioselective nucleophilic substitution of 2-position fluorine atom of 2,3,4-trifluorobenzene by (S)-glycerol

L3 ANSWER 4 OF 10 CASREACT COPYRIGHT 2003 ACS on STN


RX(7) OF 34 ...T ==&gt; Y...



RX(7) RCT T 243448-08-0

STAGE(1)  
RCT Z 7664-93-9 H2SO4  
SOL 108-24-7 AC2OSTAGE(2)  
RCT H 7732-18-5 Water  
PRO Y 243448-09-1

ACCESSION NUMBER: 131:214260 CASREACT  
TITLE: An efficient synthesis of ofloxacin and levofloxacin from 3,4-difluoroaniline  
AUTHOR(S): Adrio, Javier; Carretero, Juan C.; Ruano, Jose L.  
Garcia, Pallares, Antonio; Vicoso, Mercedes  
CORPORATE SOURCE: Departamento de Quimica Organica, Facultad de  
Cienicias, Universidad Autonoma de Madrid, Madrid,  
28049, Spain  
SOURCE: Heterocycles (1999), 51(7), 1563-1572  
CODEN: HTCWAM; ISSN: 0385-5414  
PUBLISHER: Japan Institute of Heterocyclic Chemistry  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI

L3 ANSWER 3 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)  
acetonide.


REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)  
AB The functionalization at either C-2 or C-3 of N-(tert-butoxycarbonyl)-3,4-difluoroaniline, based on its ortho-deprotonation under different exptl. conditions, is described. This process can be readily applied to the synthesis of ofloxacin [(+)-I], levofloxacin [(S)-I], and related compds.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(6) OF 48 ...R ==&gt; U...



RX(6) RCT R 86760-99-8  
RCT V 7664-93-9 H2SO4, W 108-24-7 Ac2O  
PRO U 82419-34-9  
NTE 50.degree.


ACCESSION NUMBER: 121:9414 CASREACT  
TITLE: Process for obtaining benzoxazines useful for the synthesis of ofloxacin, levofloxacin and derivatives  
INVENTOR(S): Carretero Gonzalez, Juan Carlos; Vicioso Sanchez, Mercedes; Garcia Ruano, Jose Luis  
PATENT ASSIGNEE(S): Derivados del Etilo, S.A., Spain  
SOURCE: PCT Int. Appl., 30 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: Spanish  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407873	A1	19940414	WO 1993-ES80	19931006
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, N2, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RU: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	A1	19940816	ES 1992-1983	19921007
ES 2055656	B1	19951116		
ES 2055656	A1	19950501	ES 1993-2080	19931004
ES 2069500	B1	19960301		
EP 619311	A1	19941012	EP 1993-921930	19931006
R: AT, BE, CH, DE, DK, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE	T2	19950223	JP 1993-508738	19931006
JP 07501835				

L3 ANSWER 5 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)  
AU 674541 B2 19970102 AU 1993-51118 19931006  
AU 9351518 A1 19940426  
ZA 9405098 A 19950222 ZA 1994-5088 19940713  
US 5521310 A 19960528 US 1994-244455 19940831  
AU 9665878 A1 19961212 AU 1996-65878 19960927  
AU 686955 B2 19980212  
PRIORITY APPLN. INFO.: ES 1992-1983 19921007  
ES 1993-2080 19931004  
WO 1993-ES80 19931006


OTHER SOURCE(S): MARPAT 121:9414  
GI



AB The antimicrobial agents ofloxacin [(+.-)-I], levofloxacin [(S)-I], and their derivs. and analogs are prep'd. in several steps. via (anilinomethylene)malonates II [R = H, CH2CH(OH)R1; R1 = H, C1-6 alkyl (esp. Me), C2-6 alkenyl, aryl; X = halo (esp. F)] and benzoxazines III. For example, 3,4-difluorotoluene underwent N-tert-butoxycarbonylation (98-99%), lithiation and hydroxylation in the 2-position (99%), N-deprotection (86%), and condensation with di-Et (ethoxymethylene)malonate (80-81%) to give II [R = H, X = F]. Treatment of this with NaH, LiClO4, and propylene oxide in THF gave 65% II [R = CH2CH(OH)Me, X = F], which was cyclized by PPh3 and di-Et azodicarboxylate (79%) to give III [R1 = Me, X = F]. Cyclization of the latter by AcOH-H2SO4 (73%), sapon. by HCl-AcOH (68%), and condensation with N-methylpiperazine (79%) gave (+.-)-I. By using the appropriate chiral epoxide, and proceeding via enantiomeric intermediates, enantiomeric products such as (S)-I may be obtained without resoln. (claimed, no examples).

L3 ANSWER 6 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(4) OF 11 ...G ==&gt; C...



RX(4) RCT G 86760-99-8

PRO C 82419-34-9

ACCESSION NUMBER: 106:156496 CASREACT  
TITLE: 9,10-Difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-3-carboxylic acid and its alkyl esters  
INVENTOR(S): Tanaka, Yoshiaki; Hayakawa, Isao  
PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.  
CODEN: JIXXAF


DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61246188	A2	19861101	JP 1985-187639	19850827
JP 62057636	B4	19871202		

PRIORITY APPLN. INFO.: JP 1985-187639 19850827

GI

L3 ANSWER 6 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)  
4-methyl-1-piperazinyl], were prep'd., e.g., via acetylation of 2,3-difluoro-6-nitrophenol with chloroacetone, reductive intramol. cyclocondensation, condensation of the resulting difluorodihydromethylbenzoxazine deriv. with di-Et [(dimethylamino)methylene]malonate, intramol. cyclocondensation-decarboxylation, and optional hydrolysis of I [R = Et, R1 = F].




AB The title compds. [I; R = H, alkyl; R1 = F], useful as intermediates for prepn. of the antibacterial ofloxacin [(+.-)-I; R = H, R1 =

Habte

9/23/2003

L3 ANSWER 7 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(3) OF 7 ...E ==&gt; F


RX(3) RCT E 86760-99-8  
PRO F 82419-34-9

ACCESSION NUMBER: 106:102306 CASREACT  
 TITLE: Dialkyl [(7,8-difluoro-2,3-dihydro-3-methyl-4H-1,4-benzodiazin-4-yl)methylene]malonates  
 INVENTOR(S): Tanaka, Yoshiaki; Hayakawa, Isao  
 PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.  
 CODEN: JKKCAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61246172	A2	19861101	JP 1985-187638	19850827
JP 02004222	B4	19900126		

PRIORITY APPLN. INFO.:


GI

AB The title compds. [I; R = CH:C(CO<sub>2</sub>R<sub>1</sub>)<sub>2</sub>; R<sub>1</sub> = alkyl], useful as

L3 ANSWER 7 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)  
 intermediates for the antibacterial ofloxacin, were prep'd. Thus, trifluoromethanesulfonic acid (TfCl) in Me<sub>2</sub>SO was treated with aq. KOH at 18-20.degrees. for 5 h, the resulting II (R<sub>2</sub> = OH) refluxed with chloroacetone in acetone contg. K<sub>2</sub>CO<sub>3</sub> and KI for 4 h, and the acetylxyloxy deriv. II (R<sub>2</sub> = OCH<sub>2</sub>COEt) was hydrogenated over Raney Ni to give, after treatment with 6N HCl, 1.HCl (R = H). This was condensed with Me<sub>2</sub>NCH<sub>2</sub>C(CO<sub>2</sub>Et)<sub>2</sub> in HOAc at 80-90.degrees. for 5 h to give 74.8% I [R = CH:C(CO<sub>2</sub>Et)<sub>2</sub>].

L3 ANSWER 8 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(1) OF 1 A ==&gt; B

RX(1) RCT A 86760-99-8  
PRO B 82419-34-9


ACCESSION NUMBER: 102:220985 CASREACT  
 TITLE: Pyridobenzoxazine derivatives  
 PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.  
 CODEN: JKKCAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59216890	A2	19841206	JP 1983-88826	19830520
JP 03059904	B4	19910912		

PRIORITY APPLN. INFO.:

GI


L3 ANSWER 8 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)



AB Pyridobenzoxazine derivs. I (R = Et, H) were prep'd. by treating II (R<sub>1</sub> = alkyl) or III (R<sub>2</sub>, R<sub>3</sub> = alkyl) with acid halides and H<sub>2</sub>SO<sub>4</sub>. Thus, 0.5 mL 97% H<sub>2</sub>SO<sub>4</sub> was added to a mixt. of 1 g II (R<sub>1</sub> = Et) and 2 mL AcCl at room temp. and the whole was heated for 1 h at 80-90.degrees. to give 93.9% I (R = Et).

L3 ANSWER 9 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(1) OF 1 A ==&gt; B



RX(1) RCT A 86760-99-8

PRO B 82419-34-9

ACCESSION NUMBER: 102:6509 CASREACT

TITLE: 9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid and its ethyl ester

PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59122493	A2	19840714	JP 1982-233683	19821227
JP 02012476	B4	19900320	JP 1982-233683	19821227

PRIORITY APPLN. INFO.:

GI


L3 ANSWER 9 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)



AB The title compds. I (R = H, Et) were prepd. by cyclocondensation of II [R1 = CH:C(CO2R)2 (R2 = alkyl), Q (R3, R4 = alkyl)] with acid anhydrides and H2SO4. Thus, 10 mL 97% H2SO4 was added to a mixt. of 10 g II (R1 = CH:C(CO2Et)2) and 25 mL Ac2O at room temp. to give 96.3% I (R = Et).

L3 ANSWER 10 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(5) OF 30 ...H ==&gt; F...



RX(5) RCT H 90785-36-7

PRO F 90785-09-4

ACCESSION NUMBER: 101:23460 CASREACT

TITLE: Phenyl-substituted tricyclic antibacterial agents

INVENTOR(S): Gerster, John F.; Stern, Richard M.

PATENT ASSIGNEE(S): Riker Laboratories, Inc., USA

SOURCE: U.S.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4443447	A	19840417	US 1982-436376	19821025
EP 107201	A2	19840502	EP 1983-110613	19831024
EP 107201	A3	19840822		
R: DE, FR, GB JP 59095285 US 4603199	A2	19840601	JP 1983-198968 US 1984-574045	19831024 19840126
PRIORITY APPLN. INFO.:		19860729	US 1982-436376	19821025

GI

L3 ANSWER 10 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)

AB The antibacterial (no data) tricyclic compds. I (X = O, CH2, NMe; m = 0, 1; R = H, O2N, H2N, alkyl, alkanamido, dialkylamino, HCONH, HO, alkoxy, haloalkanamido, pyrryl, n = 0, 2; R1 = H, Me, F, Cl, O2N) and their derivs. were prepd. Thus, 2,6-(O2N)PhCH3OCH2CO2Me underwent reductive cyclization to give 3,4-dihydro-5-phenyl-2H-1,4-benzoxazine, which was condensed with EtOCH:C(CO2Et)2 followed by cyclization with polyphosphoric acid and hydrolysis to give the pyridobenzoxazine II.



10/070,556

Page 9

=> log y

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

FULL ESTIMATED COST

SESSION

140.05

140.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

ENTRY

TOTAL

CA SUBSCRIBER PRICE

SESSION

-6.20

-6.20

STN INTERNATIONAL LOGOFF AT 09:52:01 ON 23 SEP 2003

Habte

9/23/2003